Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
164 participants
OBSERVATIONAL
2020-01-01
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The serum levels of some candidate cytokine variables and their relationship with some selected metabolic variables and some echocardiographic variables.
* the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation and the related cardiac remodelling.
* to analyze the correlation between selected miRNA and the selected cytokines.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
NCT04269057
Assessment of Functional Capacity and Inflammatory Markers in Women With Heart Failure With Preserved Ejection Fraction
NCT02649400
New Biomarkers in Heart- and Renal Failure
NCT02830464
The Relationship Between Heart Function and Metabolism in HFpEF Patients
NCT05053256
Pericardial Fluid Analysis in Recurrent Pericarditis
NCT06293924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with CHF and atrial fibrillation (CHF + AF)
patients with chronic heart failure (CHF) and permanent non-valvular atrial fibrillation (AF)
No interventions assigned to this group
Patients with CHF and no atrial fibrillation (CHF no-AF)
patients with CHF no prior history of atrial fibrillation
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Left ventricular ejection fraction \>40%
* New York Heart Association class II-IV symptoms
* NT-proBNP ≥600 pg/mL, or ≥900 pg/mL if AF was present on baseline electrocardiography
Exclusion Criteria
At least one of the following criteria:
* Acute heart failure
* NYHA IV
* NT-proBNP \>4000 pg/mL
* Significant valvular disease
* Mechanical prosthesis
* Cardiovascular implantable devices
* Active malignancy
* Inflammatory or infectious diseases
* Severe renal (eGFR \<30 mL/min/m²) or hepatic failure
* Chronic steroid/anti-inflammatory therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Palermo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonino Tuttolomondo
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Internal Medicine and Stroke Care Ward, Policlinic Hospital of Palermo, Sicily
Palermo, PA, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hage C, Michaelsson E, Linde C, Donal E, Daubert JC, Gan LM, Lund LH. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach. Circ Cardiovasc Genet. 2017 Feb;10(1):e001633. doi: 10.1161/CIRCGENETICS.116.001633.
Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79(3):495-502. doi: 10.1253/circj.CJ-15-0138. Epub 2015 Feb 16.
Carr JJ, Hendel RC, White RD, Patel MR, Wolk MJ, Bettmann MA, Douglas P, Rybicki FJ, Kramer CM, Woodard PK, Shaw LJ, Yucel EK; American College of Cardiology Foundation; American College of Cardiology Foundation. 2013 appropriate utilization of cardiovascular imaging: a methodology for the development of joint criteria for the appropriate utilization of cardiovascular imaging by the American College of Cardiology Foundation and American College of Radiology. J Am Coll Radiol. 2013 Jun;10(6):456-63. doi: 10.1016/j.jacr.2013.03.019. Epub 2013 Apr 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UPalermo8
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.